Evidence map›Paper›PMID 38888340›Full record

ArticleHuman molecular genetics2024

Reduced levels of MRE11 cause disease phenotypes distinct from ataxia telangiectasia-like disorder.

Andrea J Hartlerode, Ahmed M Mostafa, Steven K Orban, Rachel Benedeck, Koral Campbell, Mark J Hoenerhoff, David O Ferguson, JoAnn M Sekiguchi

Abstract read
In one paragraph

Article in Human molecular genetics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Differential expression of a disease-associatedbioRxiv : the preprint server for biology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Andrea J HartlerodeDepartment of Pathology, University of Michigan Medical School, 109 Zina Pitcher Place, Rm 2067, Ann Arbor, MI 48109-2200, United States.
Ahmed M MostafaDepartment of Pathology, University of Michigan Medical School, 109 Zina Pitcher Place, Rm 2067, Ann Arbor, MI 48109-2200, United States.
Steven K OrbanDepartment of Pathology, University of Michigan Medical School, 109 Zina Pitcher Place, Rm 2067, Ann Arbor, MI 48109-2200, United States.
Rachel BenedeckDepartment of Pathology, University of Michigan Medical School, 109 Zina Pitcher Place, Rm 2067, Ann Arbor, MI 48109-2200, United States.
Koral CampbellDepartment of Pathology, University of Michigan Medical School, 109 Zina Pitcher Place, Rm 2067, Ann Arbor, MI 48109-2200, United States.
Mark J HoenerhoffIn Vivo Animal Core, Unit for Laboratory Animal Medicine, University of Michigan Medical School, 2800 Plymouth Road, Ann Arbor, MI 48109, United States.
David O FergusonDepartment of Pathology, University of Michigan Medical School, 109 Zina Pitcher Place, Rm 2067, Ann Arbor, MI 48109-2200, United States.ORCID 0009-0004-7792-5236
JoAnn M SekiguchiDepartment of Human Genetics, University of Michigan Medical School, 109 Zina Pitcher Place, Rm 2063, Ann Arbor, MI 48109-2200, United States.ORCID 0000-0002-7178-4258

Funding

XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Eric R. Fearon · 1988 to 2026
$178.2M
The MRN complex in Lymphocyte Development and Genome StabilityR01HL153068 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SEKIGUCHI, JOANN · 2021 to 2023
$2.0M
The MRN complex in Lymphocyte Development and Genome StabilityR56HL153068 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI FERGUSON, DAVID O · 2020 to 2020
$609k
Investigating the Role of High Fat Diet in Hematopoiesis and Clonal HematopoiesisF31HL177888 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Koral Campbell · 2025 to 2026
$100k
NCI NIH HHS P30 CA046592NHLBI NIH HHS F31 HL177888NHLBI NIH HHS R01 HL153068NHLBI NIH HHS R56 HL153068NIH HHS R56HL153068Program in Biomedical SciencesUniversity of Michigan Cancer Center P30CA046592University of Michigan Medical SchoolUniversity of Michigan Transgenic Animal Model Core
6 · The paper itself

Abstract

The MRE11/RAD50/NBS1 (MRN) complex plays critical roles in cellular responses to DNA double-strand breaks. MRN is involved in end binding and processing, and it also induces cell cycle checkpoints by activating the ataxia-telangiectasia mutated (ATM) protein kinase. Hypomorphic pathogenic variants in the MRE11, RAD50, or NBS1 genes cause autosomal recessive genome instability syndromes featuring variable degrees of dwarfism, neurological defects, anemia, and cancer predisposition. Disease-associated MRN alleles include missense and nonsense variants, and many cause reduced protein levels of the entire MRN complex. However, the dramatic variability in the disease manifestation of MRN pathogenic variants is not understood. We sought to determine if low protein levels are a significant contributor to disease sequelae and therefore generated a transgenic murine model expressing MRE11 at low levels. These mice display dramatic phenotypes including small body size, severe anemia, and impaired DNA repair. We demonstrate that, distinct from ataxia telangiectasia-like disorder caused by MRE11 pathogenic missense or nonsense variants, mice and cultured cells expressing low MRE11 levels do not display the anticipated defects in ATM activation. Our findings indicate that ATM signaling can be supported by very low levels of the MRN complex and imply that defective ATM activation results from perturbation of MRN function caused by specific hypomorphic disease mutations. These distinct phenotypic outcomes underline the importance of understanding the impact of specific pathogenic MRE11 variants, which may help direct appropriate early surveillance for patients with these complicated disorders in a clinical setting.

Indexed as

Ataxia TelangiectasiaAtaxia Telangiectasia Mutated ProteinsDNA-Binding ProteinsDNA RepairMice, TransgenicMRE11 Homologue ProteinPhenotypeAnimalsCell Cycle ProteinsDisease Models, AnimalDNA Breaks, Double-StrandedHumansMiceNuclear ProteinsAtaxia Telangiectasia Mutated ProteinsCell Cycle ProteinsDNA-Binding ProteinsMre11a protein, mouseMRE11 Homologue ProteinMRE11 protein, humanNuclear Proteinsataxia telangiectasiaAT-like disorderATMDNA repair disorderMre11

Identifiers

PMID38888340
PMCPMC11373340

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.